Nektar Therapeutics has blamed manufacturing quality problems for falling response rates in a study of patients receiving its immuno-oncology drug bempegaldesleukin.
Early in a Phase I/II trial, the pegylated version of human recombinant interleukin 2 (IL-2), formerly known as NKTR-214, achieved...